MRTX
Mirati Therapeutics, Inc.
56.80
USD
This page is just a preview of the data found in TrendSpider’s full version
Mirati Therapeutics, Inc. stock is up 1.92% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 72.73% of the previous 10 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs. 0% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 02 Nov 14:45 | 19 Jan, 2024 | 60.00 | 6533 | ||
| 02 Nov 16:00 | 19 Jan, 2024 | 60.00 | 6533 | ||
| 06 Nov 15:46 | 19 Jan, 2024 | 60.00 | 7586 | ||
| 10 Nov 14:31 | 19 Jan, 2024 | 55.00 | 4027 | ||
| 15 Nov 16:45 | 17 Nov, 2023 | 55.00 | 726 | ||
| 17 Nov 17:33 | 15 Mar, 2024 | 45.00 | 662 | ||
| 17 Nov 18:43 | 17 Nov, 2023 | 50.00 | 82 | ||
| 17 Nov 20:29 | 17 Nov, 2023 | 40.00 | 2111 | ||
| 20 Nov 20:28 | 15 Dec, 2023 | 45.00 | 189 | ||
| 21 Nov 16:02 | 15 Mar, 2024 | 45.00 | 1084 |
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers. Sitravatinib, an investigational spectrum-selective kinase inhibitor, is in clinical trials for the treatment of NSCL cancer.
